Murine syngeneic tumor models are critical to novel immuno-based therapy development but the molecular and immunological features of these models are still not clearly defined. The translational relevance of differences between the models is not fully understood, impeding appropriate preclinical model selection for target validation, and ultimately hindering drug development. Across a panel of commonly-used murine syngeneic tumor models, we showed variable responsiveness to immunotherapies. We employed array comparative genomic hybridization, whole-exome sequencing, exon microarray analysis, and flow cytometry to extensively characterize these models, which revealed striking differences that may underlie these contrasting response profiles. We identified strong differential gene expression in immune-related pathways and changes in immune cell-specific genes that suggested differences in tumor immune infiltrates between models. Further investigation using flow cytometry showed differences in both the composition and magnitude of the tumor immune infiltrates, identifying models that harbor 'inflamed' and 'non-inflamed' tumor immune infiltrate phenotypes. We also found that immunosuppressive cell types predominated in syngeneic mouse tumor models that did not respond to immune-checkpoint blockade, whereas cytotoxic effector immune cells were enriched in responsive models. A cytotoxic cell-rich tumor immune infiltrate has been correlated with increased efficacy of immunotherapies in the clinic and these differences could underlie the varying response profiles to immunotherapy between the syngeneic models. This characterization highlighted the importance of extensive profiling and will enable investigators to select appropriate models to interrogate the activity of immunotherapies as well as combinations with targeted therapies in vivo.
Introduction
Recent clinical successes treating tumors with immunotherapies, including approval of the immune-checkpoint blockade antibodies ipilimumab (anti-CTLA-4) and nivolumab and pembrolizumab (anti-PD-1), demonstrate the potential to transform treatment paradigms and improve patient outcomes (1-3). These treatments represent a shift in the approach to cancer therapy as they do not target the tumor cells but instead target the immune system to circumvent inhibitory pathways that attenuate effective antitumor immune responses. Despite these successes, responses to immunotherapy usually remain restricted to a subpopulation of patients (4, 5) . In order to broaden the cancer patient population benefiting from immunotherapy, a greater understanding is needed of the factors that impact response and the potential for combination of different therapies. It is clear that T-cell infiltration varies greatly between individual tumors, patients and disease types, with some considered to harbor more immunogenic (e.g. 'hot'/'inflamed') tumors (6, 7) , characterized by greater T-cell infiltration and Th1 cytokine expression, and overlapping drivers of immunosuppression. In contrast, other tumors may be characterized by a sparse T-cell infiltrate (i.e., immunologically 'cold'), potentially as a consequence of reduced immunogenicity. The phenotype of the tumor immune infiltrate correlates with both patient prognosis (8) and outcome following immunotherapy (9) . Intrinsic tumor characteristics such as neoantigen load can also affect response to immunotherapy (10, 11) , possibly by modulating tumor immunogenicity (12) .
Human xenograft tumor models, in which human tumor cell lines are implanted in mice, have played a critical role in understanding traditional cytotoxic or targeted cancer therapies.
However, in the context of immunotherapy, these routinely used and well characterized models are not suitable, since they lack an intact immune system. Several immunocompetent mouse model systems can be used to study immunotherapies but each brings with it a series of challenges and limitations (reviewed in (13, 14) ). For example, genetically engineered mouse models (GEMMs) recapitulate the anatomical location and encompass some diseasespecific mutations frequently observed in human cancer, but they require large colonies of mice, have extended latency periods and, in contrast to the clinical setting, often display limited mutational burden and minimal genetic mosaicism (15) . Alternatively, models based on subcutaneous or orthotopic implantation of syngeneic tumor cell lines have short latency periods, are reproducible and high-throughput; on the basis of this they have been the workhorse of cancer immunology for several decades (13) . These tumor models have been invaluable in providing preclinical proof of concept for candidate immunotherapeutic drugs (16, 17) , as well as building an understanding of mechanism of action and evaluating potential biomarkers of response (18, 19) . However, to date, the majority of studies have been performed in a small number of models (compared to xenografts (14) ) and, despite their widespread use, surprisingly little is known about the genotypes and phenotypes of these syngeneic murine tumor models (14) . Ultimately, a better understanding of these models is required to enable appropriate model selection and to permit both data interpretation and extrapolation to the clinic (13, 14) .
Here, we describe a comprehensive characterization of the genomic, transcriptomic, and immunological composition of several murine syngeneic tumor models. Using flow cytometry, we characterized the tumor immune infiltrate, the spleen and tumor-draining lymph nodes (TDLN) in a panel of our most frequently-used models. This enabled us to examine whether the genotype and gene expression profile of the tumor cells associated with their immunophenotype in vivo, and determine how this related to response following immune-checkpoint blockade. This study highlights the need for extensive characterization of models used for preclinical immunotherapy research, and provides data that will, based on the proposed mechanism of action of the therapy being evaluated, support investigators in selecting appropriate models using hypothesis-driven rationales. It also forms the basis of a dataset that will increase the translational relevance of studies, by allowing parallels to be drawn between models and human disease phenotypes. Moreover, these data can be readily applied to expedite the discovery and development of novel immunotherapies by increasing the efficiency of preclinical drug development.
Materials and Methods
Tumor models. An overview of the experiments performed is shown in Supplementary Fig.   S1 . All in vivo experiments were performed in accordance with the UK Animal (Scientific Procedures) Act 1986 and the EU Directive 86/609, under a UK Home Office Project License and approved by the Babraham Institute Animal Welfare and Ethical Review Body, using guidelines outlined by Workman et al. (20) . C57BL/6 and BALB/c mice were supplied by Charles River UK at 8-10 weeks of age and > 1 8g and housed under specific pathogen-free conditions in Tecniplast Green Line IVC Sealsafe cages holding a maximum of 6 animals with irradiated aspen chip bedding, Nestlets nesting material, a cardboard tunnel and wooden chew blocks. Mice were housed on a 12/12 light/dark cycle, with ad libitum UV-treated water and RM1 rodent diet. 100 µL of cells in PBS were subcutaneously injected into the left flanks of mice (unless otherwise stated; details of the cell lines and cell numbers are in Supplementary Table S1 ).
Cells did not undergo any in vivo passaging (except for the B16F10 AP-3 cell line) and were maintained under limited passage from original stocks (typically under 5). We did not undertake additional independent validation. Tumor volume was measured using the formula (width 2 × length)/2 and tumors were collected when reaching an average of 150 mm 3 . For the Table S2 and Supplementary Dataset).
Whole-exome sequencing (WES). DNA was extracted from cell lines using the DNeasy Blood and Tissue kit (Qiagen). DNA samples were evaluated using an E-Gel (Invitrogen) and PicoGreen fluorometry to measure quality and quantity, respectively. DNA samples were then physically sheared to the desired size using a Covaris E220 Focused-ultrasonicator.
Library preparation and enrichment were carried out using an Agilent SureSelectXT Mouse All Exon 49.6Mb design, followed by sequencing on an Illumina HiSeq 2000. Basecall files (*.bcl) were de-multiplexed and converted to fastq.gz format using CASAVA v1.8.2
(Illumina). CrossMap (21) was used to lift the BED files over to mm10 reference for variant calling. The reads were aligned using BWA (22) and variants were called using FreeBayes (23) and VarDict (24) . Copy number was inferred from the exome data using Seq2C and Transcriptomics. Microarray services were provided by Almac Diagnostics, UK. RNA was extracted from the tumor, spleen and lymph node (LN) tissues from each model using RNAStat 60 (Amsbio) and quality of total RNA was determined using a 2100 Bioanalyzer (Agilent). After amplification using the WT-Ovation Pico amplification kit (NuGEN Technologies), cDNA was generated using WT-Ovation Exon module. After quality testing, cDNA was fragmented, labelled and hybridized using the FL-Ovation cDNA Biotin Module Data was log transformed and plotted using Matlab.
Statistical analyses. Flow cytometry data was analyzed in GraphPad Prism using One-Way ANOVA with Tukey's correction for multiple comparisons. For tumor growth studies, group sizes were determined using power analyses based on the variability of the models in pilot studies. Tumor growth data were log10 transformed and the effectiveness of the therapy (Tr) with respect to the baseline treatment performance was assessed with a linear mixed-effect model (30, 31) . The Yij, representing log10-transformed ith tumor volume observed at jth assessment point (T), follows the linear growth model: Yij = a0i + a1i * Tj + eij, where a0i
and a1i denote individual intercept and slope parameters, respectively, and eij ~ N(0, ) represents model error. Both intercept and slope are assumed to express random effects: a0i = g00 + g01*Tri + u0i, a1i = g10 + g11*Tri + u1i, with u0i ~ N(0, 0) and u1i ~ N(0, 1).
The parameters g00, g10, and g01, g11 represent the parameter's fixed-effects; , and 0, 1 correspond to intra-and inter-tumor variance, respectively. Models were defined as 'responsive' if the growth kinetics of the treated group compared to the control group was significantly different (P < 0.05).
Results

Model-dependent differences in anti-tumor response to anti-CTLA-4 and anti-PD-L1.
During our preclinical investigation of CTLA-4 and PD-L1 as targets for immune-checkpoint blockade, we tested the antitumor activity of surrogate antibodies in several murine syngeneic tumor models (32) . Significant tumor growth inhibition was seen following anti-CTLA-4 treatment in the CT26 (P ≤ 0.0001) and RENCA (P ≤ 0.0001) models (Fig. 1A) , whereas PD-L1 demonstrated activity only in the CT26 model (P ≤ 0.0001) (Fig. 1B ). This highlighted a need to better understand the underlying immuno-biology of murine syngeneic tumor models in order to identify potential drivers of response and enable rational selection of appropriate models for preclinical activity testing.
Genomic analysis reveals a high degree of diversity in copy number variations. We performed genome-wide aCGH analysis on 16 in vitro murine tumor cell lines to gain an understanding of broad amplification and deletion events. CNV levels were not affected by the method of tumor cell line generation since CNV frequency of carcinogen-induced CT26, genetically-induced TRAMP-C2 and spontaneous LL/2 cell lines were not markedly dissimilar (5.74%, 5.75% and 5.04% respectively) (Fig. 2) . No difference in the overall burden of genomic aberrations was seen in the CT26 cell line compared to the others (5.74%
of genes studied had CNV in CT26 vs. a mean of 6.05% across the other 15 cell lines). In order to assess CNVs against a paired background strain as opposed to a reference genome, we also investigated somatic gene copy number using whole-exome sequencing (Fig. 3A-D) .
Gain of a single gene copy was frequent (>5% of genes studied) in the RENCA and P815
lines, but amplifications of more than one extra copy much less so. We observed few deletions in the cell lines, although the most common feature across the models was the heterozygous or homozygous deletion of the Cdkn2a tumor suppressor gene (found in 9 of 11 cell lines) (Fig. 3B ).
Comparing mutational status permits model selection for tumor-targeted therapies. We also characterized the somatic mutational status of these genes using WES on a subset of the murine in vitro cell lines and further investigated 64 prominent cancer genes using targeted deep sequencing (Supplementary Table S3 Fig. S4 ). The mutational status of immune-relevant genes was also evaluated across the cell lines to investigate whether cellintrinsic genetic changes were present that could affect the ability of cell lines to recruit an immune response (Fig. 3D) . We found that the most prevalent aberrations affected the complement system, including 6 of the top 50 most mutated or amplified genes in the dataset.
Tumor-derived complement has been previously shown to both promote tumor growth but also contribute to the immune surveillance of tumors (reviewed in (38) Given that clonal selection and evolution can take place during in vivo tumor development, we performed whole-exome sequencing of CT26 cells grown in vitro and in vivo ( Fig. 3F and   G ). In the tumor, we detected 2580 out of 2955 (87.3%) somatic mutations found in the cell line. A high correlation (r = 0.766) was observed between the mutant allele frequency in vitro vs. in vivo (Fig. 3F) . Disparities in these data may be due to the use of an unfractionated tumor preparation for this analysis. There were genomic alterations in 57 cancer and immunerelevant genes found in the CT26 cell line which were not detected in the tumor, but these were mostly copy number gains that are more difficult to accurately quantify in heterogeneous in vivo samples (Fig. 3G ). There were only four somatic mutations detected in the tumor which were not in the cell line (Erbb3, Ikbkb, Mnx1 and Notch2). These could have arisen due to selective pressures at play in the tumor microenvironment. (Fig. 4A) . We also specifically investigated the expression of MHC class I and II pathway genes in the tumors and found that the B16 tumors, TC1 and LL/2 had less expression of these genes compared to the other models. The TRAMP tumors had low expression of MHC class I pathway genes, whereas the MC38 tumors had low expression of MHC class II pathway genes (Fig. 4B ).
To determine whether differences in the tumor immune infiltrate could be affecting responsiveness to immune-checkpoint blockade, we investigated the expression of immune cell type-specific genes. but having undergone a reversal of this exhaustion leading to upregulation of Ki67 and granzyme B) (44) was highest in CT26 tumors (Fig. 6D) . The absolute cell counts revealed that CT26, and to a lesser extent RENCA, tumor immune infiltrates were rich in cytotoxic immune cells whereas 4T1, B16F10 AP-3, LL/2 and MC38 are predominantly composed of cell types considered to be immunosuppressive.
In tumor lysates, the highest expression of several pro-inflammatory cytokines such as IL2, IFN , TNF and IL1 were found in the CT26, MC38, and RENCA models (Fig. 6E ). In contrast, higher levels of Th2-associated cytokines such as IL4 and IL10 were found in the MC38, 4T1 and B16F10 AP-3 models. Notably, KC/GRO, a chemoattractant for neutrophils and MDSCs, was elevated in the MDSC-rich 4T1, MC38 and LL/2 tumors.
To expand our observations, we also assessed spleens and tumor-draining lymph nodes from these animals (tissues from non-tumor bearing mice were included to highlight changes from baseline). An > 8-fold increase in splenic gMDSCs/neutrophils was observed in 4T1 tumorbearing mice compared to tumor-naïve mice (P = 0.0028) (Fig. 7A) , mirroring the predominance of these cells in the tumor (Fig. 7E) . A common finding was that spleens from tumor-bearing mice had smaller percentages of T-cells (30%) relative to tumor-naïve controls (42%) (P < 0.0001) ( Fig. 7A and B) . In tumor-naïve animals, a comparison of both genetic strains showed that BALB/c LNs had a larger proportion of CD4 + T-cells compared to C57BL/6 LNs (49.7% vs. 32.3% P < 0.0001), which had more B cells (13.9% vs. 23.6% P = 0.0003) (Fig. 7C and D) . In TDLNs, an expansion of B cells was seen vs. control tumor-naïve LNs (P = 0.0003) and this was most marked in the LL/2 and MC38 models, where it was accompanied by a corresponding decrease in the proportions of T cells and NK cells. Despite the striking contrasts in the composition of the tumor immune infiltrate (Fig. 7E and F) , this was not mirrored in the TDLNs.
Discussion:
Murine syngeneic tumor models play a central role in the advancement of novel immunotherapies, however, there is a need to fully elucidate their distinct molecular and immunological characteristics. In the present study we provide a resource to rationalize the selection of syngeneic models to test specific hypotheses; increasing the value of such studies and reducing the numbers of animals used in scientific research. In addition to characterizing the tumor microenvironment, we provide a molecular annotation of these models to describe the specific driver mutations that can be leveraged to guide immunotherapy combinations with molecularly-targeted therapies. Indeed, such combinations hold considerable promise to broaden the patient population benefiting from immunotherapy.
We have identified models in which the dominant immunological phenotype of the tumor is associated with myeloid immunosuppression, e.g., increased gMDSC and mMDSC infiltration in the 4T1, MC38, and LL/2 models. We have also identified models, particularly tumors is also translationally relevant and the CT26 or RENCA models may provide suitable settings to evaluate experimental therapeutics.
Our analysis of the somatic mutation profile of the murine cell lines reveals genetic disparities when compared to the prevalent mutations in the analogous clinical disease.
Examples of these include Trp53 in CT26 or Kras in PAN02. However, many of the genes that are commonly mutated in the clinical setting are also mutated across the preclinical models tested, offering opportunities to understand the impact of these mutations in a syngeneic setting. In particular these data will enable researchers to identify models with both the relevant pathway addiction for a defined molecular target, e.g., MEK, BRAF (45) , and overlay this with a characterized microenvironment to permit pertinent and appropriate combinations of immunotherapy and small molecule inhibitors to be evaluated.
Our study also highlights differences between the activity of immunotherapies in a preclinical immunosuppressive infiltrate. Thus, we conclude that the power of the models lies in recapitulating both a distinct phenotype of tumor microenvironment and mutation profile, rather than directly relating to the analogous human disease setting.
An interesting observation was that although the composition of the tumor microenvironment across the syngeneic models tested was strikingly varied, this contrasted starkly with the relative homogeneity in the immune phenotype observed in secondary lymphoid organs such as the tumor-draining lymph nodes and spleens. This homogeneity was also reflected by gene expression, with markedly fewer differentially-expressed gene pathways observed in these tissues when compared to those in the tumors (Supplementary Fig. S5 ). Overall, these data suggest that the greatest differences between models may result from the preferential chemoattraction, retention, and or differentiation of immune cells within the tumor microenvironment rather than from skewing of the systemic immune response, and therefore the likely factors that are driving response reside within the tumor rather than within the peripheral immune compartments. Again, this finding is also in keeping with the majority of data from the clinic to-date, where the most promising predictive biomarkers have been found in tumor tissue, rather than in peripheral blood (49) .
Several of our findings are concordant with previous observations, such as the predominant loss of Cdkn2a among the cell lines, which has been described to result from cell culture selective pressures (50) and is also prevalent across multiple human cancer types (51) .
Previous studies have also shown that different syngeneic tumor models can respond differently to treatment (16, 49, 52) . It has been hypothesized that these differences could be due to variability in immunogenicity of the models (13) but, until now, the similarities and differences between these models have not been comprehensively characterized. The most extensive study, to our knowledge, included 6 commonly-used syngeneic models with analysis limited to the expression of 27 immune-related genes and staining for 4-6 immune cell types by immunohistochemistry and flow cytometry (52) . We also saw a high level of agreement in somatic mutation results with previous genetic characterization of the CT26 cell line, with >60% of mutated genes matching those in the study by Castle et al. (53, 54) .
Although another study described fewer somatic mutations in CT26 and 4T1, 80-90% of those mutated genes matched our results (54) and the relative proportions of somatic mutations was conserved, with >10 fold more mutations in CT26 compared to the 4T1.
Likewise, comparison of our somatic mutation results in the ATCC B16F10 line to those in Castle et al. (55) showed over 90% concordance in the mutated genes found in both studies including Brca2, Trp53, Jak3, Atm, Pten and Mdm1. Disparities in somatic mutations between studies could be due to differences in cut-off levels, sensitivity and methodology, as well as cell line divergence. Our profiling of CNV, using both aCGH and WES analysis paired with the BALB/c mouse background, did not show the same large regions of triploidy and tetraploidy in CT26 seen by Castle et al. (53) . However, for such multichromosomal regions it is unlikely that this would be due to divergence in the CT26 cell lines, but rather due to methodological differences such as stringency of CNV calling.
In conclusion, we provide extensive characterization of a range of commonly used murine syngeneic models to rationalize model selection based on the biology of the tumor cell and the tumor microenvironment. Moreover, a greater understanding of model biology allows more robust alignment between response, mechanism of action, and the biology of human cancer subtypes that may ultimately improve the efficiency of drug discovery. 
